Apollo hospitals Enterprise has received a maintained Buy rating from BofA Securities, with the brokerage firm setting a target price of ₹9,600 for the healthcare major. The recommendation suggests a potential upside of over 25% from current levels, reflecting strong confidence in the company's growth trajectory and operational improvements.

Key Investment Drivers

BofA Securities' positive stance is anchored on multiple growth catalysts that are expected to drive Apollo Hospitals' performance in the coming periods. The brokerage has identified several strategic areas where the company is positioned to deliver substantial value creation.

Margin Expansion in Existing Operations

The brokerage firm expects Apollo Hospitals to benefit from margin expansion in its existing hospital network. This improvement comes despite the company facing losses from new hospital operations, which is typical during the initial phases of hospital establishment. The mature hospitals in Apollo's portfolio are expected to drive profitability improvements through operational efficiencies and higher utilization rates.

Digital Segment Growth Prospects

A significant component of BofA Securities' bullish outlook centers on Apollo Hospitals' digital initiatives. The firm anticipates strong growth in the digital segment, with projections indicating that this business vertical will achieve cash breakeven by Q1FY27. This timeline reflects the company's strategic focus on expanding its digital healthcare offerings and leveraging technology to enhance patient care and operational efficiency.

HealthCo Re-rating Potential

BofA Securities also highlights the potential for HealthCo re-rating based on retail-like metrics. This perspective suggests that Apollo Hospitals could benefit from higher valuation multiples as the market recognizes the company's diversified healthcare ecosystem. The retail-like metrics approach could lead to a fundamental shift in how investors value the company's various business segments, potentially unlocking additional shareholder value.

Apollo Hospitals Enterprise Limited has delivered impressive financial results for Q3FY26, demonstrating strong growth momentum across its integrated healthcare platform. The company announced its unaudited financial results for the three and nine months ended December 31, 2025, showcasing robust performance in all business verticals.

Financial Performance Highlights

The company's consolidated performance for Q3FY26 showed remarkable growth across key metrics:

For the nine-month period ended December 31, 2025, the consolidated results continued to reflect strong performance:

Interim Dividend Declaration

The Board of Directors declared an interim dividend of Rs. 10 per share, representing 200% of the face value of Rs. 5 per share for the financial year 2025-26. The key dates for the dividend payment are:

Segment-wise Performance

Healthcare Services (Hospitals)

The healthcare services division maintained strong growth with revenue of Rs. 31,832 million in Q3FY26 compared to Rs. 27,850 million in Q3FY25, representing 14% YoY growth. EBITDA increased 18% YoY to Rs. 7,898 million with margins at 24.8%. The division operates 8,072 beds across the network with an overall occupancy rate of 67%.

Apollo Health and Lifestyle Limited

The diagnostics and retail healthcare segment showed robust performance with revenue growing 20% YoY to Rs. 4,668 million. EBITDA improved significantly by 39% to Rs. 476 million, with margins expanding to 10.2%.

Apollo HealthCo

The digital healthcare and pharmacy distribution platform delivered strong results with revenue growing 20% YoY to Rs. 28,274 million. EBITDA increased substantially to Rs. 1,279 million compared to Rs. 566 million in the previous year, with margins at 4.5%. The platform added 185 net new stores during the quarter, bringing the total to 7,113 stores.

Operational Milestones

Apollo Hospitals launched a cutting-edge 250-bed quaternary care hospital in Pune, representing the first phase of a planned 400-bed capacity. The facility features advanced surgical robotics, precision oncology, and comprehensive critical care with 100+ ICU beds.

The company continues to lead in transplant care as the world's busiest solid organ transplant program, performing an average of five solid organ transplants daily. The group has completed over 21,000 kidney transplants and more than 5,000 liver transplants, becoming the first hospital group in India to reach this milestone.

Regulatory Impact

The company reported an exceptional item of Rs. 192 million in consolidated results due to the implementation of new Labour Codes notified by the Government of India on November 21, 2025. This one-time impact resulted from increased gratuity and leave liabilities arising from the consolidation of twenty-nine existing labour laws into a unified framework.

Corporate Developments

The Board approved a Composite Scheme of Arrangement involving the demerger of identified business undertakings, primarily representing the omni-channel pharmacy distribution business and digital health platform business. The scheme has received necessary approvals from stock exchanges, and the company has filed an application before the National Company Law Tribunal for final approval.

Analyst Call Recording and Transcript Available

Pursuant to Regulations 30 and 46(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has made available both the audio recording and transcript of the analyst call on the financial results for the three and nine months ended December 31, 2025. The presentation was conducted on February 11, 2026, and the transcript is now accessible on the company's website for stakeholder reference and transparency.